创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

汪小又, 刘鑫龙, 李翀. 多肽/微型蛋白类导向分子的研究进展[J]. 药学进展, 2019, 43(10): 767-776.
引用本文: 汪小又, 刘鑫龙, 李翀. 多肽/微型蛋白类导向分子的研究进展[J]. 药学进展, 2019, 43(10): 767-776.
WANG Xiaoyou, LIU Xinlong, LI Chong. Research Progress on Peptide/Mini-protein as Targeting Molecules[J]. Progress in Pharmaceutical Sciences, 2019, 43(10): 767-776.
Citation: WANG Xiaoyou, LIU Xinlong, LI Chong. Research Progress on Peptide/Mini-protein as Targeting Molecules[J]. Progress in Pharmaceutical Sciences, 2019, 43(10): 767-776.

多肽/微型蛋白类导向分子的研究进展

Research Progress on Peptide/Mini-protein as Targeting Molecules

  • 摘要: 多肽药物因其相对分子质量小、生物活性高、易于修饰和规模化制备等特点,是新药研究的重要方向之一。除了直接作为候选药物或小分子药物设计的前体之外,多肽在药物开发中还有一类十分重要的应用:作为导向分子。多肽类导向分子与病灶部位靶标的特异性结合能够介导小分子药物或递药系统更有效地被靶细胞摄取,从而有望实现高效低毒的治疗。综述近年来多肽类导向分子的来源、优化以及发展趋势,以期为相关研究提供参考。

     

    Abstract: Peptide drugs have been one of the important fields of new drug research because of their small molecular weight, high biological activity, easy modification and large-scale preparation. In addition to being directly used as drug candidates or precursors for small molecule drug design, peptides have a very important application in drug development, i.e. as targeting molecules. The specific binding of the polypeptide-directed molecule to the target of the lesion site can mediate more efficient accumulation of the small molecule drug or drug delivery system in the target site, thereby achieving high efficiency and low toxicity. In this paper, the source, optimization and application progress of peptides as targeting molecules in recent years are reviewed so as to provide reference for related researches.

     

/

返回文章
返回